Marta Penas-Prado, M.D.
Dr. Marta Penas-Prado is an Associate Research Physician in the Rare Tumor Patient Engagement Network (RTPEN) of the Neuro-Oncology Branch. She is a Neurologist and sub-specialty fellowship-trained Neuro-Oncologist. She has expertise in the development and execution of clinical trials, with a focus on gliomas, adult medulloblastoma, and other rare central nervous system (CNS) tumors.
Dr. Penas-Prado has broad experience in developing and conducting clinical trials for patients with gliomas and other central nervous system (CNS) tumors. She has been a principal investigator in multiple investigator-initiated, industry-sponsored, and cooperative clinical trials, exploring the use of targeted therapies, adoptive cell therapy and other immuno oncologic therapies.
Selected Key Publications
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.Cancer. Epub ahead of print, 2018. [ Journal Article ]
- Psychooncology. Epub ahead of print, 2018. [ Journal Article ]
- J Neurooncol. 139(3): 713-720, 2018. [ Journal Article ]
Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma.Pituitary. 19(4): 415-21, 2018. [ Journal Article ]
- Brain Tumor Pathol. 32(2): 105-11, 2015. [ Journal Article ]
Dr. Penas-Prado graduated with a medical degree from Facultad de Medicina y Cirugia, Universidad de Santiago de Compostela, Spain. She completed a neurology residency at Hospital 12 de Octubre, Universidad Complutense de Madrid, Spain. She completed her clinical neuro-oncology fellowship training at The University of Texas MD Anderson Cancer Center, Houston, Texas. Prior to joining CCR, Dr. Penas-Prado was Associate Professor and Clinical Research Director of Neuro-Oncology at MD Anderson Cancer Center. Currently, she serves as an Associate Research Physician at the Neuro-Oncology Branch. She specializes in rare CNS tumors. Her research focuses on developing clinical trials for primary brain tumor patients.